{"title":"Mersana Therapeutics与Endo的抗体-药物偶联合作提高了知名度","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1700","DOIUrl":null,"url":null,"abstract":"Mersana Therapeutics has formed a collaboration with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs) against a single, undisclosed cancer target. Mersana will combine its Fleximer® conjugation technology with anticancer antibodies discovered by Endo to produce Fleximer-ADC candidates for development, manufacturing and commercialisation by Endo. With this deal, Mersana has emerged as a competitor of Seattle Genetics and ImmunoGen in the development of ADCs.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mersana Therapeutics Raises Profile with Antibody-Drug Conjugate Collaboration with Endo\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I3.1700\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mersana Therapeutics has formed a collaboration with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs) against a single, undisclosed cancer target. Mersana will combine its Fleximer® conjugation technology with anticancer antibodies discovered by Endo to produce Fleximer-ADC candidates for development, manufacturing and commercialisation by Endo. With this deal, Mersana has emerged as a competitor of Seattle Genetics and ImmunoGen in the development of ADCs.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-03-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I3.1700\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I3.1700","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mersana Therapeutics Raises Profile with Antibody-Drug Conjugate Collaboration with Endo
Mersana Therapeutics has formed a collaboration with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs) against a single, undisclosed cancer target. Mersana will combine its Fleximer® conjugation technology with anticancer antibodies discovered by Endo to produce Fleximer-ADC candidates for development, manufacturing and commercialisation by Endo. With this deal, Mersana has emerged as a competitor of Seattle Genetics and ImmunoGen in the development of ADCs.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
